Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Galectin-3 genetic variants are associated with platinum-based chemotherapy response and prognosis in patients with NSCLC.

Cellular oncology (Dordrecht, Netherlands) - 1 Jun 2012

Wu Fenglei, Hu Nan, Li Yu, Bian Baoxiang, Xu Guanghui, Zheng Yitong

Abstract excerpt

AIM: To explore the association between the galectin-3 genetic polymorphisms and Platinum-based chemotherapy response as well as the prognosis of non-small cell lung cancer (NSCLC). METHOD: Three hundred twenty patients with Stage III (A+B) or IV NSCLC were enrolled. A Platinum-based chemotherapy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Carcinoma, Non-Small-Cell Lung
Share to Galectin 3

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Platinum

Share to Prognosis

Share to Proportional Hazards Models

Share to Survival Analysis

Source

Open in PubMed Open full text

Identifiers

PMID: 22476961
DOI: 10.1007/s13402-012-0075-7
PMCID: PMC12994991

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22476961-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Galectin-3 genetic variants are associated with platinum-based chemotherapy response and prognosis in patients with NSCLC.PMID 22476961Read ↗

XRCC1 Arg399Gln and clinical outcome of platinum-based treatment for advanced non-small cell lung cancer: a meta-analysis in 17 studies.Semantic proximity Read ↗

Prediction models for platinum-based chemotherapy response and toxicity in advanced NSCLC patients.Semantic proximity Read ↗

Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients.Semantic proximity Read ↗

Lung cancer, platinum analog-based frontline treatment and pharmacogenetic limitations.Semantic proximity Read ↗

Effect of GSTP1 and ABCC2 Polymorphisms on Treatment Response in Patients with Advanced Non-Small Cell Lung Cancer Undergoing Platinum-Based Chemotherapy: A Study in a Chinese Uygur Population.Semantic proximity Read ↗

ATP7B rs9535826 is associated with gastrointestinal toxicity of platinum-based chemotherapy in nonsmall cell lung cancer patients.Semantic proximity Read ↗

The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.Semantic proximity Read ↗

Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients.Semantic proximity Read ↗

Association of GSTP1 and XRCC1 gene polymorphisms with clinical outcome of advanced non-small cell lung cancer patients with cisplatin-based chemotherapy.Semantic proximity Read ↗

Association of CCND1 rs9344 polymorphism with lung cancer susceptibility and clinical outcomes: a case-control study.Semantic proximity Read ↗

The T393C polymorphism of GNAS1 as a predictor for chemotherapy sensitivity and survival in advanced non-small-cell lung cancer patients treated with gemcitabine plus platinum.Semantic proximity Read ↗

Gene-gene and gene-environment interactions influence platinum-based chemotherapy response and toxicity in non-small cell lung cancer patientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.